Clinical trials: Solid Tumors (Phase 1)
Neoplasms Malignant
A Study of B1962, a PD-L1/VEGF Bispecific Antibody Fusion Protein, for Advanced Solid Tumors
This study is to characterize the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of B1962, a PD-L1/VEGF bispecific antibody fusion protein, as a single agent in adult subjects with advanced solid tumor…
- Trial name
- NCT05650385
- Testing
- B1962
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Tasly Biopharmaceuticals Co., Ltd.
Advanced Solid Tumors
A Study of FDA022-BB05 in Subjects With Advanced Solid Malignant Tumors
This is a Phase 1, open-label and two-part study to evaluate the safety, tolerability, pharmacokinetics and efficacy of FDA022-BB05 in participants with advanced/metastatic solid malignant tumors.
- Trial name
- NCT05564858
- Testing
- FDA022 Monoclonal antibody-drug conjugate for injection Phase Ia, FDA022 Monoclonal antibody-drug conjugate for injection Phase Ib
- Where
- China
- Volunteers
- 107 people
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Hepatocellular Carcinoma, Squamous Cell Non-Small Cell Lung Cancer
A Study of ZW251 in Participants With Advanced Solid Tumors
The purpose of this study is to find out if ZW251, an antibody-drug conjugate targeting glypican-3 (GPC3), is safe and can treat participants with advanced cancers, including hepatocellular carcinoma (HCC), squamous cell…
- Conditions
- Hepatocellular Carcinoma, Squamous Cell Non-Small Cell Lung Cancer, Germ Cell Tumor
- Trial name
- NCT07164313
- Testing
- ZW251
- Where
- 25 sites in United States, Ireland and 4 more
- Volunteers
- 140 people
- Sponsor
- Zymeworks BC Inc.
Large Cell Neuroendocrine Carcinoma, Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC)
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [212Pb]Pb-MP0712, in patients aged ≥18 years with Small Cell Lung Cancer and other locally advanced or metastatic DLL3…
- Conditions
- Large Cell Neuroendocrine Carcinoma, Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), Small Cell Lung Cancer (SCLC)
- Trial name
- NCT07278479
- Testing
- [212Pb]Pb-MP0712, [203Pb]Pb-MP0712
- Where
- 8 sites in United States
- Volunteers
- 138 people
- Sponsor
- Molecular Partners AG
Neoplams
Phase 1 Study of MST-168 in Participants With Advanced Solid Malignant Tumors
A Phase 1, multiregional, open-label study of MST-168 in participants with target-driven advanced solid tumors. The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics, immunogenicity…
- Trial name
- NCT07644650
- Testing
- MST-168
- Where
- China
- Volunteers
- 420 people
- Sponsor
- Mabsoft Therapeutics (Shanghai) Co., Ltd.
Locally Advanced or Metastatic Solid Tumors
A Dose-escalation Study of LUNA18 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).
This is a Phase 1 dose-escalation and cohort expansion study that will evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of LUNA18 when administered as a single agent or in combination…
- Trial name
- NCT05012618
- Testing
- LUNA18, Cetuximab
- Where
- 20 sites in United States, Japan
- Volunteers
- 128 people
- Sponsor
- Chugai Pharmaceutical
Carcinoma, Pancreatic Ductal, Colorectal Neoplasms
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
The purpose of this study is to learn about the safety and effects of the study medicine when given alone or together with other anti-cancer therapies. Anti-cancer therapy is a type of treatment to stop the growth of cancer.
- Conditions
- Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT06704724
- Testing
- PF-07985045, Gemcitabine, Nab-paclitaxel
- Where
- 13 sites in United States, Puerto Rico
- Volunteers
- 30 people
- Sponsor
- Pfizer
Advanced Cancer, Metastatic Cancer
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: Find the recommended dose of ART0380 that can be given safely to participants…
- Conditions
- Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cancer
- Trial name
- NCT04657068
- Testing
- ART0380, Gemcitabine, Irinotecan
- Where
- 88 sites in United States, France and 2 more
- Volunteers
- 542 people
- Sponsor
- Artios Pharma Ltd
Tumors, Lymphoma
Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors
This is an open-label, multicenter, dose-escalation, safety, pharmacokinetics, and pharmacodynamics study.
- Trial name
- NCT00345189
- Testing
- CNF2024
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 70 people
- Sponsor
- Biogen
Tumor Infiltrating Lymphocytes, Safety
A Phase I Study of GC101 TIL in Advanced Solid Tumors
20-60 participants are expected to be enrolled for the Phase I clinical trial which is further divided into two parts: a "3+3" dose escalation study and an expanded enrollment study.
- Conditions
- Tumor Infiltrating Lymphocytes, Safety, Advanced Solid Tumor, Immunotherapy
- Trial name
- MIZAR-001 (NCT05417750)
- Testing
- TIL therapy
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Shanghai Juncell Therapeutics
Metastatic or Locally Advanced Unresectable Solid Tumors
First-in-Human Study of MS201408-0005A as Single Agent and in Combinations
This is a Phase I, open-label study to determine the safety, tolerability, pharmacokinetic (PK), pharmacodynamics (PD), and preliminary antitumor activity of MS201408-0005A as single agent (Part IA only) and in combination with…
- Trial name
- NCT03306420
- Testing
- M4112
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Solid Tumors, Advanced Solid Tumors
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
To evaluate the safety, tolerability, and DLTs and determine the MTD and/or RDE(s) of INCA33890 in participants with select advanced or metastatic solid tumors.
- Conditions
- Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors
- Trial name
- NCT05836324
- Testing
- INCA33890, bevacizumab, FOLFIRI
- Where
- 39 sites in United States, China and 7 more
- Volunteers
- 570 people
- Sponsor
- Incyte Corporation
Advanced Solid Cancers
An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers
The main purpose of this study is to characterize the safety, tolerability, dose limiting toxicities, best route of administration, maximum tolerated dose, maximum administered dose, or alternative dose of BMS-986301 alone or in…
- Trial name
- NCT03956680
- Testing
- BMS-986301, Nivolumab, Ipilimumab
- Where
- 5 sites in United States, Canada
- Volunteers
- 54 people
- Sponsor
- Bristol-Myers Squibb
Malignant Neoplasmas, Solid Tumors
Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid Tumors
Treatment of cancer is often more effective when two or more drugs are used together. For example, when gemcitabine, an approved drug, and ON 01910.Na, a new investigational anti-cancer drug, are used together to treat cancer…
- Trial name
- NCT01125891
- Testing
- gemcitabine, ON 01910.Na
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- Traws Pharma, Inc.
Advanced Solid Malignancies
Clinical Trial to Evaluate Safety and Tolerability of OratecanTM in Patients With Advanced Solid Malignancies (Oratecan-102)
The main objective of this study is to determine the maximum tolerated dose (MTD) of OratecanTM. Eligible subjects of this study are patients with histologically or cytologically confirmed malignant solid tumor refractory to…
- Trial name
- NCT00986843
- Testing
- HM30181AK tablet + Irinotecan tablets
- Where
- South Korea
- Volunteers
- 14 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
MSI-H or dMMR Advanced Solid Tumors
This Study Aims to Evaluate the Efficacy and Safety of QLS1317 in Patients With MSI-H/dMMR Advanced Solid Tumors.
The goal of this study aims to evaluate the efficacy and safety of QLS1317 in patients with MSI-H/dMMR advanced solid tumors who failed standard treatment.
- Trial name
- NCT07552376
- Testing
- QLS1317
- Volunteers
- 120 people
- Sponsor
- Shanghai Qilu Pharmaceutical Research and Development Center LTD
Advanced or Metastatic Solid Tumors
A Study to Investigate the Safety, Tolerability and Efficacy of HLX60 Combination With HLX10 in Subjects With Advanced or Metastatic Solid Tumors
The purpose of the study is to evaluate the safety and tolerability of HLX60 combined with HLX10 in order to determine the maximum tolerated dose (MTD) and Recommended Phase 2 dose (RP2D) and to evaluate the preliminary efficacy…
- Trial name
- NCT05483530
- Testing
- HLX60 combined with HLX10
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- Shanghai Henlius Biotech
Tumours, Gynecological
A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)
Advanced solid tumors are cancers that have spread to other parts of the body. While many treatments exist, most people become resistant to them, and the cancer returns.
- Trial name
- NCT06796907
- Testing
- Mo-Rez, Dostarlimab, Bevacizumab
- Where
- 83 sites in United States, Argentina and 21 more
- Volunteers
- 305 people
- Sponsor
- GlaxoSmithKline
Advanced Solid Tumors
Study of CM529D1 in Participants With Advanced Solid Tumors
This is interventional study to evaluate the safety and tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy of CM529D1 in participants with advanced solid tumors.
- Trial name
- NCT07893171
- Testing
- CM529D1
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Keymed Biosciences Co.Ltd
Advanced/Metastatic Solid Tumors, Relapse/Refractory Lymphoma
First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma
For solid tumors and lymphoma, respectively: This study is to evaluate the safety and tolerability of EMB-07 and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D).
- Trial name
- NCT05607498
- Testing
- EMB07
- Where
- 10 sites in Australia, China
- Volunteers
- 150 people
- Sponsor
- EpimAb Biotherapeutics (Suzhou)Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.